BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

Dan Spiegelman stepped down as EVP and CFO at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to pursue other interests. SVP, Finance and Chief Accounting Officer Brian Mueller will serve as acting CFO as the rare diseases company...
BioCentury | Aug 21, 2019
Distillery Therapeutics

LGALS3 identified as Huntington disease target

DISEASE CATEGORY: Neurology INDICATION: Huntington disease (HD) Inhibiting the lectin LGALS3 could treat HD, which is caused by aggregation of mutant HTT. Plasma levels of LGALS3 protein were higher in 26 symptomatic HD patients than...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BioCentury | Mar 9, 2019
Finance

Seventure maps its microbiome future

Seventure Partners' second microbiome-based fund aims to foster a generation of companies beyond those focused only on live therapeutics. On March 5, the firm announced a first close of Health for Life Capital II, intended...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
BioCentury | Nov 2, 2018
Financial News

Galecto raises €79M to advance pipeline of galectin inhibitors

Looking to advance several clinical candidates, Galecto Biotech AB (Copenhagen, Denmark) raised €79 million ($91.1 million) on Oct. 26 in a tranched series C round. Galecto CEO Hans Schambye declined to disclose details regarding the...
BioCentury | Nov 1, 2018
Finance

OrbiMed’s NASH Terns

Terns Pharmaceuticals Inc. brings a dual U.S.-China strategy and a diverse pipeline to OrbiMed’s non-alcoholic steatohepatitis investment portfolio. OrbiMed co-led the biotech’s $80 million series B on Oct. 30 with fellow new investor Vivo Capital....
Items per page:
1 - 10 of 33
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

CNS disorders company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced Mark Schneyer as its first CBO. He was VP, business development at the Upjohn unit of Pfizer Inc. (NYSE:PFE). Hansa Biopharma AB (SSE:HNSA) said Achim Kaufhold will...
BioCentury | May 28, 2020
Management Tracks

Quick departure for Semerjian as Immunomedics CEO; plus Ziopharm, Kinnate, Applied Therapeutics, Relmada, AskBio and more

Less than two months after becoming president and CEO of Immunomedics Inc. (NASDAQ:IMMU), Harout Semerjian is stepping down because of “unfortunate significant logistical obstacles presented by the COVID-19 pandemic,” according to the cancer company. Executive...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

Dan Spiegelman stepped down as EVP and CFO at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to pursue other interests. SVP, Finance and Chief Accounting Officer Brian Mueller will serve as acting CFO as the rare diseases company...
BioCentury | Aug 21, 2019
Distillery Therapeutics

LGALS3 identified as Huntington disease target

DISEASE CATEGORY: Neurology INDICATION: Huntington disease (HD) Inhibiting the lectin LGALS3 could treat HD, which is caused by aggregation of mutant HTT. Plasma levels of LGALS3 protein were higher in 26 symptomatic HD patients than...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BioCentury | Mar 9, 2019
Finance

Seventure maps its microbiome future

Seventure Partners' second microbiome-based fund aims to foster a generation of companies beyond those focused only on live therapeutics. On March 5, the firm announced a first close of Health for Life Capital II, intended...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
BioCentury | Nov 2, 2018
Financial News

Galecto raises €79M to advance pipeline of galectin inhibitors

Looking to advance several clinical candidates, Galecto Biotech AB (Copenhagen, Denmark) raised €79 million ($91.1 million) on Oct. 26 in a tranched series C round. Galecto CEO Hans Schambye declined to disclose details regarding the...
BioCentury | Nov 1, 2018
Finance

OrbiMed’s NASH Terns

Terns Pharmaceuticals Inc. brings a dual U.S.-China strategy and a diverse pipeline to OrbiMed’s non-alcoholic steatohepatitis investment portfolio. OrbiMed co-led the biotech’s $80 million series B on Oct. 30 with fellow new investor Vivo Capital....
Items per page:
1 - 10 of 33